The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discoverin ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 Trial Final long-term efficacy and ...

Daiichi Sankyo has shared final long-term data from the Phase III ENLIVEN clinical trial (NCT02371369). In the study, treatment with Turalio (pexidartinib) showed a sustained clinical benefit in ...

CDE’s approval is for the treatment of adult patients with tenosynovial giant cell tumors (TGCTs) requiring systemic treatment. Pimicotinib, which is in development by Abbisko Therapeutics, was ...

Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo (p ...

Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive tumor originating in the synovial lining of the joint, bursa, and tendon sheath. Since TGCT typically impacts individuals ...

Discover how pimicotinib offers significant improvements for patients with tenosynovial giant cell tumor in recent trial results.

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.